Table 1.
Patient and donor characteristics (with interquartile ranges where appropriate) for the 60 recipients with early graft loss (<90 days post-liver transplant).
| AMR Changes Present | Possible Contribution from DSA | No Definitive Evidence of AMR | ||
|---|---|---|---|---|
| Number | 3 | 3 | 54 | |
| Age | 56 (47–58) | 52 (40–55) | 50 (41–58) | |
| Model for End-Stage Liver Disease | 27(12–40) | 16 (13–33) | 17 (12–26) | |
| Pre-operative dialysis | 1(33%) | 0% | 3 (5%) | |
| Cold ischemia time (hours) | 11.8 (7.5–12.2) | 8.4 (7.8–8.7) | 9.6 (8.2–11.7) | |
| Warm ischemia time (minutes) | 62 (52–84) | 52 (50–55) | 56 (46–68) | |
| OR time (hours) | 7.8 (5.1–7.9) | 6.3(4.8–8.2) | 6.8(5.8–7.8) | |
| Time to graft loss (days) | 19 (19–40) | 3 (0–54) | 5.5 (3–19) | |
| Male Sex# | 0% | 1(33%) | 38 (70%) | |
| Race | African-American | 0% | 0% | 1(2%) |
| Hispanic | 0% | 1(33%) | 8(15%) | |
| Other | 0% | 0% | 1(2%) | |
| Caucasian | 3 (100%) | 2(67%) | 44(81%) | |
| Liver Disease | Hepatitis C | 0% | 2(67%) | 14(26%) |
| PSC/PBC/AIH | 2 (67%) | 0% | 9(17%) | |
| Alcohol | 1(33%) | 0% | 8(15%) | |
| NASH/CC | 0% | 1(33%) | 6(11%) | |
| Metabolic/congenital | 0% | 0% | 3(5%) | |
| Other | 0% | 0% | 14(26%) | |
| Hepatocellular Carcinoma | 0% | 0% | 5(9%) | |
| Donor age | 42 (37–45) | 56(55–59) | 50(36–59) | |
| Donor race | Caucasian | 3 (100%) | 2(67%) | 37(68%) |
| African-American | 0% | 1(33%) | 10(19%) | |
| Other | 0% | 0% | 7(13%) | |
| Induction | 1(33%) | 1(33%) | 16(30%) | |
| CNI* | Tacrolimus | 66% | 33% | 29% |
| Cyclosporine | 0% | 0% | 52% | |
| None | 33% | 66% | 19% | |
| Steroids* | 100% | 66% | 60% | |
| Sirolimus* | 0% | 0% | 12% | |
| Mycophenolate* | 0% | 66% | 35% | |
#
P=0.02; no other statistically significant differences were found between the groups.
*
Day 1 immunosuppression
CNI, calcineurin inhibitor; PSC, primary sclerosing cholangitis; PBC, primary biliary cirrhosis; AIH, autoimmune hepatitis; NASH, non-alcoholic steatohepatitis; CC, cryptogenic cirrhosis